The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | How have novel agents changed the paradigm for treating older or frail patients with CLL?
In this video, Florian Simon, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the impact of novel agents on the treatment of older or frail patients with chronic lymphocytic leukemia (CLL), highlighting that age alone is not a reliable indicator of a patient’s fitness level. Dr Simon emphasizes the importance of considering a patient’s overall fitness when choosing treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
